CAN STANDARDISATION BE ACHIEVED? ASSESSMENT OF PLASMA CELL MYELOMA MINIMAL RESIDUAL DISEASE TESTING BY FLOW CYTOMETRY: AN INTERNATIONAL INTER-LABORATORY STUDY

EHA Library, Stuart Scott, 215045

MP0250 IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED-AND-REFRACTORY MULTIPLE MYELOMA: FIRST SAFETY AND EARLY EFFICACY ANALYSIS OF MP0250-CP201

EHA Library, Monika Szarejko, 215046

STATIN USE IMPROVES MYELOMA-SPECIFIC SURVIVAL AND IS SAFE TO USE IN LYMPHOMA: A POPULATION-BASED STUDY OF 20,464 PATIENTS WITH LYMPHOID MALIGNANCIES DIAGNOSED IN SWEDEN 2007-2013

EHA Library, Elsa Brånvall, 215047

A PROSPECTIVE ANALYSIS ON THE FREQUENCY AND PREDICTIVE VALUE OF MINIMAL RESIDUAL DISEASE ASSESSMENT BY FLOW CYTOMETRY AND PET-CT IMAGING AMONG MYELOMA PATIENTS ON/OFF MAINTENANCE

EHA Library, MERAL BEKSAC, 215048

EARLY RELAPSE IS A POWERFUL INDEPENDENT NEGATIVE PREDICTOR FOR OVERALL SURVIVAL IN MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL AGENTS

EHA Library, Eirini Katodritou, 215049

SENSIVITY AND CLINICAL VALUE OF POSITRON EMISSION TOMOGRAPHY / COMPUTED TOMOGRAPHY AND WHOLE BODY MAGNETIC RESONANCE IMAGING TO ASSESS BONE DISEASE IN NEWLY DIAGNOSED MULTIPLE MYELOMA.

EHA Library, Elena Fernández Poveda, 215050

PHARMACOLOGIC TARGETING OF NEOPLASTIC STEM CELLS IN HUMAN MAST CELL LEUKEMIA

EHA Library, Gregor Eisenwort, 215051

THE PHENOTYPIC PROFILE OF ACUTE MYELOID LEUKEMIA SECONDARY TO CHRONIC MYELOPROLIFERATIVE NEOPLASMS: RESULTS OF A MULTI-CENTER STUDY

EHA Library, Francesco Mannelli, 215052

POTENT ACTIVITY OF AZACITIDINE ON LEUKEMIA-INITIATING CELLS IN A XENOGRAFT MODEL OF JUVENILE MYELOMONOCYTIC LEUKEMIA

EHA Library, Miriam Erlacher, 215053

MUTATIONAL MECHANISMS OF EZH2 INACTIVATION IN MYELOID NEOPLASMS

EHA Library, Andrew Chase, 215054

MUTANT CALRETICULINS ASSOCIATED WITH MYELOPROLIFERATIVE NEOPLASM RETAIN IN-VITRO CHAPERONE ACTIVITY

EHA Library, Anita Roy, 215055

SDF1 ΑLPHA-INDUCED CHEMOTAXIS OF JAK2-V617F POSITIVE CELLS IS DEPENDENT ON BRUTON'S TYROSINE KINASE AND PHOSPHOLIPASE C GAMMA 1

EHA Library, Subbaiah chary Nimmagadda, 215056

HDAC INHIBITION BY VALPROIC ACID DECREASES JAK2V617F LEVELS IN MYELOPROLIFERATIVE NEOPLASMS VIA UP-REGULATION OF MIR-101, IN VIVO AND IN VITRO

EHA Library, Elisabetta De Marinis, 215057

RESULTS FROM 48-WEEK FOLLOW-UP OF THE EXPAND STUDY: A PHASE 1B, OPEN-LABEL, DOSE-FINDING STUDY OF RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS AND LOW PLATELET COUNTS (50-99 × 10^9/L) AT BASELINE

EHA Library, Peter te Boekhorst, 215058

AVAPRITINIB (BLU-285), A SELECTIVE KIT INHIBITOR, IS ASSOCIATED WITH HIGH RESPONSE RATE AND TOLERABLE SAFETY PROFILE IN ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM): RESULTS OF A PHASE 1 STUDY

EHA Library, Maureen Conlan, 215059

DURABILITY OF SPLEEN RESPONSE MAY AFFECT OUTCOME OF RUXOLITINIB-TREATED PATIENTS WITH MYELOFIBROSIS: RESULTS FROM A MULTICENTRE STUDY ON 284 PATIENTS

EHA Library, Francesca Palandri, 215060

PREDICTORS OF RESPONSE TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF) IN THE PHASE 3B EXPANDED-ACCESS JUMP STUDY

EHA Library, Haifa Kathrin Al-Ali, 215061

HIGH RISK OF RECURRENT VENOUS THROMBOEMBOLISM IN BCR-ABL-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS AFTER TERMINATION OF ANTICOAGULATION

EHA Library, Kai Wille, 215062

RESULTS FROM ONGOING PHASE 1/2 TRIAL OF SL-401 IN PATIENTS WITH INTERMEDIATE OR HIGH RISK RELAPSED/REFRACTORY MYELOFIBROSIS

EHA Library, Naveen Pemmaraju, 215063

BONE MARROW MORPHOLOGY IN PATIENTS WITH POLYCYTHEMIA VERA RESISTANT TO FIRST AND SECOND LINE THERAPIES

EHA Library, Hans Michael KVASNICKA, 215064

WHO 2016 CLASSIFICATION IN 80 CHILDREN AND ADOLESCENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS.

EHA Library, Michelina SANTOPIETRO, 215065

SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH DIPSS LOW-RISK MYELOFIBROSIS (MF) IN THE PHASE 3B EXPANDED-ACCESS JUMP STUDY

EHA Library, Haifa Kathrin Al-Ali, 215066

PRIMARY THERAPY AND SURVIVAL IN PRIMARY MYELOFIBROSIS: A NATIONWIDE POPULATION-BASED ANALYSIS AMONG 1,445 PATIENTS DIAGNOSED IN THE NETHERLANDS BETWEEN 2001 AND 2015

EHA Library, Avinash Dinmohamed, 215067

RUXOLITINIB COMPARED WITH BEST AVAILABLE THERAPY FOR POLYCYTHAEMIA VERA PATIENTS RESISTANT OR INTOLERANT TO HYDROXYCARBAMIDE IN MAJIC - AN INVESTIGATOR-LED RANDOMISED TRIAL

EHA Library, Claire Harrison, 215068

RESULTS FROM ONGOING PHASE 1/2 TRIAL OF SL-401 IN PATIENTS WITH RELAPSED/REFRACTORY CMML

EHA Library, Mrinal Patnaik, 215069

DABRAFENIB IN PEDIATRIC PATIENTS WITH BRAF V600–POSITIVE LANGERHANS CELL HISTIOCYTOSIS

EHA Library, Darren Hargrave, 215070

COMPARISON OF RUXOLITINIB AND REAL-WORLD BEST AVAILABLE THERAPY IN TERMS OF OVERALL SURVIVAL AND THROMBOSIS IN PATIENTS WITH POLYCYTHEMIA VERA WHO ARE RESISTANT OR INTOLERANT TO HYDROXYUREA

EHA Library, Alberto Alvarez, 215071

RELATIONSHIP BETWEEN MPN PAIN AND EMOTIONAL HEALTH: AN ANALYSIS BY THE MPN QUALITY OF LIFE INTERNATIONAL STUDY GROUP

EHA Library, Robyn Scherber, 215072

ANALYSIS OF IPSET-THROMBOSIS VS R-IPSET-THROMBOSIS IN A POPULATION OF 776 ESSENTIAL THROMBOCYTHEMIA PATIENTS - A MULTICENTER RETROSPECTIVE STUDY.

EHA Library, Marta Sobas, 215073

SKEWED RATIO BETWEEN TYPE 1 AND TYPE 2 CALR MUTATIONS IN ESSENTIAL THROMBOCYTOSIS PATIENTS WITH CONCOMITANT JAK2 V617F MUTATION

EHA Library, Anni Aggerholm, 215074

CLONAL B-CELL LYMPHOCYTOSIS OF MARGINAL ZONE ORIGIN: NEW INSIGHTS INTO A NOVEL AND STILL ENIGMATIC ENTITY

EHA Library, Aliki Xochelli, 215075

BUILDING PRECLINICAL MOUSE MODELS FOR MANTLE CELL LYMPHOMA

EHA Library, Tim Pieters, 215076

THE AXL TYROSINE KINASE INHIBITOR, BGB324, INDUCES CELL DEATH IN MANTLE CELL LYMPHOMA

EHA Library, Pascal Gelebart, 215077

MODELLING MYD88 P.L265P DRIVEN LYMPHOMA

EHA Library, Gero Knittel, 215078

CD3 BISPECIFIC ANTIBODY SCREEN IDENTIFIES CD20 AS THE MOST EFFICIENT TARGET FOR ELIMINATION OF B CELL MALIGNANCIES; PRE-CLINICAL EVALUATION OF DUOBODY-CD3XCD20

EHA Library, Patrick Engelberts, 215079

TG-1701 A NOVEL, ORALLY AVAILABLE, AND COVALENTLY-BOUND BTK INHIBITOR

EHA Library, Emmanuel Normant, PhD, 215080

DASATINIB ENHANCES ANTHRACYCLIN-BASED CHEMOTHERAPY IN PRE-CLINICAL MODELS OF T-CELL LYMPHOMA

EHA Library, Cristiana Carniti, 215081

ELEVATED SERUM IL-8, IL-10, IL-22, AND MCP-1 ARE ASSOCIATED WITH INFERIOR CLINICAL OUTCOMES IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA

EHA Library, Jun Ho Yi, 215082

BIOMARKER ANALYSES OF PATIENTS WITH RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA, FOLLICULAR LYMPHOMA, OR RICHTER’S TRANSFORMATION TREATED WITH IBRUTINIB + NIVOLUMAB IN THE PHASE 1/2A LYM1002 STUDY

EHA Library, Anas Younes, 215083

SYSTEMS BIOLOGY ANALYSIS OF RESPONSIVENESS OF NON-HODGKIN LYMPHOMA B-CELL LINES TO CD37 TARGETING RADIOIMMUNOTHERAPY

EHA Library, Sebastian Patzke, 215084

CBL-MZ IS NOT A SINGLE BIOLOGICAL ENTITY: EVIDENCE FROM GENOMIC ANALYSIS AND PROLONGED CLINICAL FOLLOW UP

EHA Library, Jonathan Strefford, 215085

HETEROGENEOUS MUTATIONS AT RHOA EXON 2 REVEALED BY TARGETED SEQUENCING OF CELL FREE DNA AND PERIPHERAL BLOOD MONONUCLEAR CELL DNA IN PERIPHERAL T-CELL LYMPHOMA

EHA Library, Simon D Wagner, 215086

PROGRAMMED DEATH-1 PATHWAY UP-REGULATION BY LENALIDOMIDE IN ACTIVATED LOW-GRADE LYMPHOMA CELLS

EHA Library, Fortunato Morabito, 215087

THE EFFECT OF DUVELISIB, A DUAL INHIBITOR OF PI3K-DELTA,GAMA ON COMPONENTS OF THE TUMOR MICROENVIRONMENT IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA

EHA Library, Carla Casulo, 215088

INCORPORATION OF GENE EXPRESSION PROFILING FOR CELL-OF-ORIGIN DETERMINATION USING FORMALIN-FIXED PARAFFIN-EMBEDDED TISSUE SECTIONS IN ROUTINE WORK-UP OF DIFFUSE LARGE B-CELL LYMPHOMA CASES

EHA Library, Ryan S. Robetorye, 215089

DIFFUSE LARGE B CELL LYMPHOMA WITH CONCORDANT BONE MARROW INVOLVEMENT. UTILITY OF FLOW CYTOMETRY, CLINICAL AND BIOLOGICAL EVALUATION.

EHA Library, Lucia Morais, 215090

DUVELISIB INHIBITION OF CHEMOKINES IN PATIENTS WITH CLL AND INHL

EHA Library, David Weaver, 215091

ACCURATE GCB/ABC CLASSIFICATION OF DE NOVO DIFFUSE LARGE B-CELL LYMPHOMA WITH ABERRANT CD10+ MUM1+ PHENOTYPE BY RT-MLPA

EHA Library, Yannick Le Bris, 215092

IMMUNOGLOBULIN KAPPA DELETING ELEMENT (IGK-KDE) REARRANGEMENTS AS POSSIBLE TARGET FOR MINIMAL RESIDUAL DISEASE (MRD) EVALUATION IN MANTLE CELL LYMPHOMA (MCL)

EHA Library, Irene Della Starza, 215093

CIRCULATING MICRORNAS (MIRNAS) IN ITP PATIENTS BEFORE AND AFTER TREATMENT WITH THROMBOPOIETIN RECEPTOR AGONISTS (TPO-RAS)–DIAGNOSTIC AND PROGNOSTIC VALUE

EHA Library, Lamya Garabet, 215094

A SINGLE-ARM, OPEN-LABEL, LONG-TERM EFFICACY AND SAFETY STUDY OF SUBCUTANEOUS (SC) ROMIPLOSTIM IN CHILDREN WITH IMMUNE THROMBOCYTOPENIA (ITP)

EHA Library, Michael Tarantino, 215095

THE BURDEN OF DISEASE AND IMPACT OF IMMUNE THROMBOCYTOPENIA (ITP) ON PATIENT QUALITY OF LIFE AND PRODUCTIVITY: RESULTS FROM THE ITP WORLD IMPACT SURVEY (I-WISH)

EHA Library, Nichola Cooper, 215096

FINAL SAFETY AND EFFICACY DATA OF LONG-TERM OPEN-LABEL DOSING OF SUBCUTANEOUS (SC) ROMIPLOSTIM IN CHILDREN WITH IMMUNE THROMBOCYTOPENIA (ITP)

EHA Library, Michael Tarantino, 215097

AVATROMBOPAG DEMONSTRATES SUPERIORITY TO PLACEBO FOR THE TREATMENT OF CHRONIC IMMUNE THROMBOCYTOPENIC PURPURA IN A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

EHA Library, Wojciech Jurczak, 215098

A PHASE 1B, OPEN-LABEL, DOSE-ESCALATION STUDY OF PRTX-100, A HIGHLY PURIFIED FORM OF STAPHYLOCOCCAL PROTEIN A (SPA), IN ADULT PATIENTS WITH PERSISTENT/CHRONIC IMMUNE THROMBOCYTOPENIA (ITP)

EHA Library, Nichola Cooper, 215099

RITUXIMAB IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: STANDARD DOSE VERSUS LOW DOSE

EHA Library, Saikat Datta, 215100

SAFETY PROFILE OF CAPLACIZUMAB DURING THE PHASE III HERCULES STUDY: FREQUENCY OF ADVERSE EVENTS ACCORDING TO STUDY PERIOD

EHA Library, Filip Callewaert, 215101

LOW-DOSE RITUXIMAB PLUS PREDNISOLONE YIELDS HIGHER SUSTAINED RESPONSE RATES THAN PREDNISOLONE MONOTHERAPY AS FRONTLINE THERAPY IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA

EHA Library, Saikat Datta, 215102

EXTENDED FOLLOW UP OF PATIENTS TREATED IN THE RITUXIMAB AS SECOND-LINE TREATMENT FOR ADULT IMMUNE THROMBOCYTOPENIA – THE RITP STUDY

EHA Library, Waleed Ghanima, 215103

EPIDEMIOLOGY AND MANAGEMENT OF PRIMARY IMMUNE THROMBOCYTOPENIA: REAL WORLD DATA FROM THE UK ITP REGISTRY

EHA Library, Abbas Zaidi, 215104

PREDICTORS OF SUCCESS FOR SPLENECTOMY IN CHILDHOOD AUTOIMMUNE CYTOPENIA

EHA Library, Nathalie Aladjidi, 215105

PHASE II, MULTIPLE-DOSE STUDY OF ANTI-FCRN ANTIBODY, ROZANOLIXIZUMAB (UCB7665), IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: SECOND INTERIM ANALYSIS

EHA Library, Tadeusz Robak, 215106

SWI IDENTIFIES BRAIN MICROHAEMORRHAGES IN ASYMPTOMATIC PATIENTS WITH IMMUNE THROMBOCYTOPENIA (ITP)

EHA Library, Camelia Vladescu, 215107

DEFINING TREATMENT SUCCESS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA RECEIVING THROMBOPOIETIN RECEPTOR AGONIST THERAPY: RESULTS FROM A MODIFIED DELPHI CONSENSUS PANEL

EHA Library, Anuja Roy, 215108

MYH9-RELATED THROMBOCYTOPENIA: FOUR NOVEL VARIANTS AFFECTING THE TAIL DOMAIN OF THE NON-MUSCLE MYOSIN HEAVY CHAIN IIA ASSOCIATE WITH A MILD CLINICAL EVOLUTION OF THE DISEASE

EHA Library, Carlo Zaninetti, 215109

REAL-WORLD TAPERING AND DISCONTINUATION OF THROMBOPOIETIN RECEPTOR AGONIST THERAPY IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA: A SURVEY OF HEMATOLOGISTS IN THE UNITED KINGDOM

EHA Library, Anuja Roy, 215110

ELTROMBOPAG TREATMENT IN PATIENTS WITH PERSISTENT VERSUS CHRONIC IMMUNE THROMBOCYTOPENIA: COMPARISON OF EFFICACY AND SAFETY RESULTS FROM THE PHASE III EXTEND STUDY AND A PHASE IV STUDY

EHA Library, Raymond Wong, 215111

PERFORMANCE OF THE ISTH BLEEDING ASSESSMENT TOOL IN PREDICTING THE PRESENCE OF INHERITED PLATELET FUNCTION DISORDERS

EHA Library, Maaike Blaauwgeers, 215112

SPLENECTOMY IN COMPARISON WITH RITUXIMAB AS A SECOND LINE TREATMENT FOR RELAPSED OR REFRACTORY ITP

EHA Library, Martina Morić-Perić, 215113

IMMUNE THROMBOCYTOPENIA PURPURA (ITP) PATIENT JOURNEY – ROUTINE CLINICAL CARE FOR CHRONIC ITP IN DENMARK, 2009-2015

EHA Library, Henrik Frederiksen, 215114

DISEASE MANAGEMENT OF PATIENTS WITH IMMUNE THROMBOCYTOPENIA - RESULTS OF A REPRESENTATIVE RETROSPECTIVE SURVEY IN GERMANY

EHA Library, Anne Sophie Kubasch, 215115

PREDICTIVE FACTORS FOR SUCCESSFUL SPLENECTOMY OUTCOME – SYSTEMATIC REVIEW

EHA Library, Mirjana Mitrovic, 215116

CARDIOVASCULAR AND BLEEDING OUTCOMES IN A NORDIC COHORT OF ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (CITP)

EHA Library, Kasper Adelborg, 215117

PLATELET COUNT EVOLUTION AS A PREDICTOR OF OUTCOME AFTER RITUXIMAB TREATMENT IN CHRONIC IMMUNE THROMBOCYTOPENIA

EHA Library, Shixuan Wang, 215118

SUSTAINED PLATELET COUNTS ≥100X109/L DURING ELTROMBOPAG TREATMENT IN PATIENTS WITH PERSISTENT/CHRONIC IMMUNE THROMBOCYTOPENIA (ITP): RESULTS FROM A 2-YEAR, PHASE IV, OPEN-LABEL STUDY

EHA Library, Tahir Shamsi, 215119

LONG-TERM EFFICACY AND SAFETY OF ROMIPLOSTIM FOR TREATMENT OF CHRONIC IMMUNE THROMBOCYTOPENIA

EHA Library, Sergey Semochkin, 215120

ITP SECONDARY TO ALEMTUZUMAB-INDUCED RENAL TRANSPLANT: OUTCOME OF 31 PATIENTS

EHA Library, Elisa Lucchini, 215121

AN OBSERVATIONAL, NON-INTERVENTIONAL CLINICAL PRACTICE STUDY OF ROMIPLOSTIM IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIC PURPURA (ITP) – PLATON FINAL RESULTS

EHA Library, Barbara Skopec, 215122

COMBINED/CONCOMITANT THERAPY FOR RAPID RECOVERY IN PATIENTS WITH REFRACTORY/RECURRENT IMMUNE THROMBOCYTOPENIA (ITP) AND MODERATE/SEVERE BLEEDING: AN OBSERVATIONAL STUDY

EHA Library, Mariasanta Napolitano, 215123

BRENTUXIMAB VEDOTIN IN RELAPSED/REFRACTORY SYSTEMIC ANAPLASTIC LARGE-CELL LYMPHOMA: A COST-EFFECTIVENESS ANALYSIS

EHA Library, Lung-I Cheng, 215124

REAL-WORLD OUTCOMES ASSOCIATED WITH LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE IN THE TREATMENT OF NEWLY DIAGNOSED MULTIPLE MYELOMA WITHOUT STEM CELL TRANSPLANT

EHA Library, Ajai Chari, 215125

CPX-351 FOR THE TREATMENT OF NEWLY DIAGNOSED, THERAPY-RELATED ACUTE MYELOID LEUKEMIA (TAML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC): NUMBER NEEDED TO TREAT (NNT) TO PREVENT ONE DEATH

EHA Library, Arthur Louie, 215126

QUALITY OF LIFE IN NEWLY DIAGNOSED AND RELAPSED DANISH MULTIPLE MYELOMA PATIENTS - A NATIONAL LONGITUDINAL STUDY OF DANISH MYELOMA STUDY GROUP

EHA Library, Lene Kongsgaard Nielsen, 215127

COMBINED VISIBLE AND INFRA RED LOW LEVEL LASER THERAPY FOR PREVENTION OF ORAL MUCOSITIS IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION.

EHA Library, Mehdi Tabarraei, 215128

IMPACT OF CLINICAL AND SOCIAL FACTORS ON QUALITY OF LIFE (QOL) IN PATIENTS (PTS) WITH TRANSFUSION-DEPENDENT (TDT) AND NON-TRANSFUSION-DEPENDENT (NTDT) BETA-THALASSEMIA: A MULTICENTER STUDY

EHA Library, Vip Viprakasit, 215129

RAPID AND COMPREHENSIVE GENOMIC CHARACTERIZATION OF HEMATOLOGICAL MALIGNANCIES USING A HYBRID-CAPTURE TARGETED SEQUENCING PANEL

EHA Library, Michaela Gruber, 215130

UNTANGLING HOSPITALIZATIONS IN SYSTEMIC AMYLOIDOSIS: PATIENT CHARACTERISTICS, ECONOMIC COST AND CLINICAL OUTCOMES

EHA Library, Tiffany P. Quock, 215131

ERECTILE DISFUNCTION IN HEMATOLOGICAL MALIGNANCIES

EHA Library, Frosina Krstanoska, 215132

THE BURDEN OF DISEASE IN PYRUVATE KINASE DEFICIENCY: PATIENTS’ PERCEPTION OF THE IMPACT ON HEALTH-RELATED QUALITY OF LIFE

EHA Library, Sam Salek, 215133

RELEVANT REDUCTION OF POMALIDOMIDE-RELATED NEUTROPENIA BY INTENSIVE USE OF MYELOID GROWTH FACTOR

EHA Library, MARINA PARISI, 215134

REAL WORLD EVIDENCE BASED COST-EFFECTIVENESS ANALYSES (CEA) OF NILOTINIB VERSUS IMATINIB AS FIRST-LINE TREATMENT IN THE MANAGEMENT OF CHRONIC MYELOID LEUKEMIA (CML) IN CHINA

EHA Library, Ming Jian, 215135

LIVING AND COPING WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A QUALITATIVE STUDY OF GREEK PATIENTS’ EXPERIENCES ON BEHALF OF ERIC, THE EUROPEAN RESEARCH INITIATIVE ON CLL

EHA Library, Aliki Xochelli, 215136

COMPARISON OF THE PAPER-BASED AND ELECTRONIC VERSION OF A NEW PATIENT-REPORTED OUTCOME MEASURE IN HAEMATOLOGICAL MALIGNANCY FOR USE IN CLINICAL PRACTICE, HM-PRO: AN EQUIVALENCE STUDY

EHA Library, Pushpendra Goswami, 215137

A SEER-MEDICARE ANALYSIS OF NOVEL TREATMENT USE AND ASSOCIATED OUTCOMES AMONG AFRICAN AMERICAN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Sikander Ailawadhi, 215138

USE OF PATIENT-CENTRED OUTCOMES IN THE MANAGEMENT OF ANEMIA: A SYSTEMATIC REVIEW

EHA Library, Phillip Staibano, 215139

COST UTILITY ANALYSIS OF THE USE OF LETERMOVIR FOR THE PROPHYLAXIS OF CYTOMEGALOVIRUS IN PATIENTS UNDERGOING ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANT – TWO SCENARIO ANALYSES FROM ITALY

EHA Library, Fabio Ciceri, 215140

ERN-EUROBLOODNET: THE EUROPEAN REFERENCE NETWORK ON RARE HEMATOLOGICAL DISEASES. 1ST YEAR OF IMPLEMENTATION

EHA Library, María del Mar Mañú Pereira, 215141

PALLIATIVE CARE INDICATION IN NON-HODGKIN'S LYMPHOMA PATIENTS: A COMPARISON TO SOLID TUMOR PATIENTS

EHA Library, Lucia Morais, 215142

EVALUATING THE CORRELATION BETWEEN FATIGUE AND QUALITY OF LIFE IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AND TREATED WITH BIOSIMILAR EPOETIN ALFA FOR CHEMOTHERAPY-INDUCED ANEMIA: THE CIROCO STUDY

EHA Library, Kamel Laribi, 215143

DIAGNOSIS DISCLOSURE IN PATIENTS WITH HEMATOLOGICAL CANCERS IN INDIA

EHA Library, Chepsy Philip, 215144